Key result
[11C]Metomidate PET demonstrated a sensitivity of 0.89 and specificity of 0.96 for proving the adrenocortical origin of adrenal lesions.
Why the study?
Does [11C]Metomidate PET accurately identify adrenocortical origin in patients with adrenal tumors?
Observational (n=173)
No
Does [11C]Metomidate PET accurately identify adrenocortical origin in patients with adrenal tumors?
MTO-PET is a highly sensitive and specific imaging modality for diagnosing adrenocortical tumors, which may aid in the work-up of adrenal incidentalomas.
No takes yet. Share an insight, caveat, or question.
MTO-PET may aid adrenocortical tumor differentiation in incidentalomas; leaves open routine adoption pending prospective trials.
Hennings et al. (2006) conducted an observational in Adrenal tumors (n=173). [11C]Metomidate Positron Emission Tomography (MTO-PET) was evaluated on Proving adrenocortical origin of the lesions. [11C]Metomidate PET demonstrated a sensitivity of 0.89 and specificity of 0.96 for proving the adrenocortical origin of adrenal lesions.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: